Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chain termination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Chain termination. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000639-30 Sponsor Protocol Number: AB20009 Start Date*: 2022-01-12
    Sponsor Name:AB Science
    Full Title: A 96-Weeks, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the T...
    Medical condition: Patients with primary progressive or secondary progressive multiple sclerosis without relapse
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Prematurely Ended) GR (Trial now transitioned) BG (Completed) NO (Prematurely Ended) PT (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005971-11 Sponsor Protocol Number: AP101-02 Start Date*: 2021-10-20
    Sponsor Name:AL-S Pharma, AG
    Full Title: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000775-32 Sponsor Protocol Number: H-030-014 Start Date*: 2013-08-13
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection
    Medical condition: Prevention of primary Clostridium difficile infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    20.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    20.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    20.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    20.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed) DK (Completed) PL (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-001810-24 Sponsor Protocol Number: BO25323 Start Date*: 2014-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND ...
    Medical condition: chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) EE (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-000167-69 Sponsor Protocol Number: AIC649-02-II-01 Start Date*: 2021-06-30
    Sponsor Name:AiCuris Anti-Infective Cures AG
    Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ...
    Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084467 Asymptomatic SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004923-34 Sponsor Protocol Number: RSV-MVA-004 Start Date*: 2022-07-07
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age
    Medical condition: respiratory syncytial virus disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000849-23 Sponsor Protocol Number: HC-G-H-1403 Start Date*: 2017-08-21
    Sponsor Name:B. Braun Melsungen AG
    Full Title: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION
    Medical condition: Chronic intestinal failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002987-14 Sponsor Protocol Number: BN40423 Start Date*: 2019-02-13
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST ...
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) NL (Completed) AT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004664-18 Sponsor Protocol Number: NEOD001-OLE251 Start Date*: 2017-08-08
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
    Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001736-95 Sponsor Protocol Number: ACCORD-2-001,Sub002,003,006 Start Date*: 2020-04-28
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients
    Medical condition: COVID 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002154-70 Sponsor Protocol Number: CP40559 Start Date*: 2019-10-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016138-29 Sponsor Protocol Number: APL-C-001-09 Start Date*: 2010-05-06
    Sponsor Name:Pharma Mar, S.A.
    Full Title: “Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma”.
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) ES (Completed) AT (Completed) NL (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) GR (Completed) IE (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001283-37 Sponsor Protocol Number: GE-ARNICA-2008 Start Date*: 2007-09-24
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users)
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019715 Hepatic viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001160-28 Sponsor Protocol Number: MedOPP376 Start Date*: 2020-04-09
    Sponsor Name:Medica Scientia Innovation Research S.L. (MEDSIR)
    Full Title: A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pn...
    Medical condition: Coronavirus Disease 2019 (COVID-19)-Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002230-32 Sponsor Protocol Number: Start Date*: 2020-06-23
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Rapid Experimental Medicine for COVID-19
    Medical condition: COVID-19
    Disease:
    Population Age: Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000326-54 Sponsor Protocol Number: C16014 Start Date*: 2013-10-08
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Dia...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000048-23 Sponsor Protocol Number: P2-IMU-838-PMS Start Date*: 2021-11-04
    Sponsor Name:Immunic AG
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
    Medical condition: Progressive forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003225-41 Sponsor Protocol Number: 233AS102 Start Date*: 2017-04-10
    Sponsor Name:Biogen Idec Research Limited
    Full Title: An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sc...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10077024 Familial amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) DK (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003350-25 Sponsor Protocol Number: SPON1751-19 Start Date*: 2019-09-05
    Sponsor Name:Cardiff University
    Full Title: An open label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line...
    Medical condition: Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:55:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA